Akebia Doses First Patient in Phase 2 Trial for Rare Kidney Diseases
Event summary
- Akebia Therapeutics dosed the first patient in its Phase 2 basket trial for ebribafusp, targeting IgA nephropathy, lupus nephritis, and C3 glomerulopathy.
- The open-label trial aims to enroll up to 30 patients and report initial data in 2027.
- Ebribafusp is designed to inhibit complement activation in kidney tissue without systemic suppression.
- Akebia acquired global rights to ebribafusp from Q32 Bio in November 2025.
The big picture
Akebia's Phase 2 trial for ebribafusp marks a strategic pivot toward rare kidney diseases, leveraging its acquired asset to target unmet needs. The focus on tissue-specific complement inhibition could reduce infection risks associated with systemic treatments, positioning Akebia in a niche but growing segment of nephrology therapeutics. Success here would validate Akebia's acquisition strategy and expand its pipeline beyond its core focus.
What we're watching
- Clinical Efficacy
- How ebribafusp's tissue-specific inhibition will impact proteinuria and kidney function in rare kidney diseases.
- Regulatory Pathway
- Whether the Phase 2 data will support further development and potential approval for multiple indications.
- Competitive Positioning
- The pace at which Akebia can differentiate ebribafusp in a crowded complement-inhibition space.
Related topics